ArticleMedComm2026

Perioperative Camrelizumab and Apatinib for High-Risk Resectable Hepatocellular Carcinoma: A Phase II Study.

Yunlong Cui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.